BR112023018530A2 - Conjugado de ação prolongada, composição farmacêutica e seu uso - Google Patents

Conjugado de ação prolongada, composição farmacêutica e seu uso

Info

Publication number
BR112023018530A2
BR112023018530A2 BR112023018530A BR112023018530A BR112023018530A2 BR 112023018530 A2 BR112023018530 A2 BR 112023018530A2 BR 112023018530 A BR112023018530 A BR 112023018530A BR 112023018530 A BR112023018530 A BR 112023018530A BR 112023018530 A2 BR112023018530 A2 BR 112023018530A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
long action
conjugate
long
action conjugate
Prior art date
Application number
BR112023018530A
Other languages
English (en)
Portuguese (pt)
Inventor
Ram Lee A
Hyeon PARK Da
Lim Oh Euh
Young Kim Jin
Sub Park Jun
Yun Kim Sang
Ho Heo Yong
Yon KIM Yu
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of BR112023018530A2 publication Critical patent/BR112023018530A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/55IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2013IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
BR112023018530A 2021-03-31 2022-03-31 Conjugado de ação prolongada, composição farmacêutica e seu uso BR112023018530A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20210042305 2021-03-31
PCT/KR2022/004620 WO2022211537A1 (ko) 2021-03-31 2022-03-31 신규한 면역 활성 인터루킨 2 아날로그 결합체 및 이의 제조 방법

Publications (1)

Publication Number Publication Date
BR112023018530A2 true BR112023018530A2 (pt) 2023-10-10

Family

ID=83459706

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023018530A BR112023018530A2 (pt) 2021-03-31 2022-03-31 Conjugado de ação prolongada, composição farmacêutica e seu uso

Country Status (15)

Country Link
US (1) US12599675B2 (https=)
EP (1) EP4316528A4 (https=)
JP (1) JP2024512418A (https=)
KR (2) KR102680146B1 (https=)
CN (1) CN116916969A (https=)
AR (1) AR125263A1 (https=)
AU (1) AU2022209248B2 (https=)
BR (1) BR112023018530A2 (https=)
CA (1) CA3205058C (https=)
CL (1) CL2023002504A1 (https=)
IL (1) IL304365B2 (https=)
MX (1) MX2023010926A (https=)
PE (1) PE20250672A1 (https=)
WO (1) WO2022211537A1 (https=)
ZA (1) ZA202307219B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022009123A1 (en) * 2020-07-09 2022-01-13 Eutilex Co., Ltd. Il-2 variants
AU2023408268A1 (en) 2022-12-23 2025-07-10 Hanmi Pharm. Co., Ltd. Formulations comprising immune stimulating IL-2 analog conjugates
KR20240137492A (ko) * 2023-03-07 2024-09-20 한미약품 주식회사 암의 예방 또는 치료를 위한 인터루킨 2 아날로그 또는 이의 결합체 및 면역관문 억제제의 병용 요법
JP2026509259A (ja) * 2023-03-07 2026-03-17 ハンミ ファーマシューティカル カンパニー リミテッド インターロイキン2アナログ又はその結合体を含む癌予防又は治療用薬学的組成物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
KR100507796B1 (ko) * 2003-04-03 2005-08-17 한미약품 주식회사 생체내 반감기가 증가된 peg-생리활성 폴리펩티드 동종이량체 결합체 및 이의 제조방법
HUE029139T2 (hu) * 2011-02-10 2017-02-28 Roche Glycart Ag Mutáns interleukin-2 polipeptidek
MX385194B (es) * 2014-02-21 2025-03-14 Nektar Therapeutics India Pvt Ltd Agonistas il-2rbeta-selectivos en combinación con un anticuerpo anti-ctla-4 o un anticuerpo anti-pd-1.
GB2538666A (en) 2014-07-21 2016-11-23 Delinia Inc Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases
EP3943101A1 (en) 2014-10-21 2022-01-26 SciClone Pharmaceuticals International Ltd. Treatment of cancer with immune stimulator alpha thymosin peptide
WO2017052329A1 (en) * 2015-09-24 2017-03-30 Hanmi Pharm. Co., Ltd. Protein complex by use of a specific site of an immunoglobulin fragment for linkage
KR102687530B1 (ko) 2016-05-04 2024-07-25 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
MX386014B (es) * 2016-08-10 2025-03-18 Univ Ajou Ind Academic Coop Found Citocina fusionada a fc heterodimérico, y composición farmacéutica que comprende la misma.
US11077172B2 (en) * 2016-11-08 2021-08-03 Delinia, Inc. IL-2 variants for the treatment of psoriasis
US20200299349A1 (en) * 2017-11-21 2020-09-24 The Board Of Trustees Of The Leland Stanford Junior University Partial agonists of interleukin-2
WO2019185705A1 (en) * 2018-03-28 2019-10-03 Ascendis Pharma A/S Il-2 conjugates
MX2021000801A (es) * 2018-07-24 2021-04-12 BioNTech SE Agonistas de il2.
WO2020057646A1 (zh) * 2018-09-21 2020-03-26 信达生物制药(苏州)有限公司 新型白介素2及其用途
US20220025007A1 (en) * 2018-12-21 2022-01-27 Hanmi Pharm. Co., Ltd. Novel immunosuppressive interleukin 2
TW202115105A (zh) 2019-06-24 2021-04-16 德商拜恩迪克Rna製藥有限公司 Il2激動劑
KR20220044534A (ko) * 2019-08-13 2022-04-08 엘피스 바이오파마슈티컬즈 조작된 인터류킨-2 수용체 베타 효능제

Also Published As

Publication number Publication date
CA3205058C (en) 2024-04-09
ZA202307219B (en) 2024-10-30
PE20250672A1 (es) 2025-03-04
KR20240099117A (ko) 2024-06-28
EP4316528A4 (en) 2026-03-11
CA3205058A1 (en) 2022-10-26
AU2022209248B2 (en) 2023-06-29
CN116916969A (zh) 2023-10-20
US20240009317A1 (en) 2024-01-11
AR125263A1 (es) 2023-06-28
EP4316528A1 (en) 2024-02-07
CL2023002504A1 (es) 2024-01-26
KR20220136285A (ko) 2022-10-07
IL304365A (en) 2023-09-01
AU2022209248A1 (en) 2022-10-20
IL304365B1 (en) 2024-12-01
IL304365B2 (en) 2025-04-01
MX2023010926A (es) 2023-09-27
JP2024512418A (ja) 2024-03-19
KR102680146B1 (ko) 2024-07-04
WO2022211537A1 (ko) 2022-10-06
US12599675B2 (en) 2026-04-14
TW202304521A (zh) 2023-02-01

Similar Documents

Publication Publication Date Title
BR112023018530A2 (pt) Conjugado de ação prolongada, composição farmacêutica e seu uso
BR112021017408A2 (pt) Compostos tricíclicos fundidos úteis como agentes anticancerosos
CL2024003552A1 (es) Anticuerpo anti-ccr8; método de producción; composición farmacéutica; y su uso.
BR112022002496A2 (pt) Compostos deuterados para uso no tratamento de câncer
BR112018075653A2 (pt) anticorpos anti-b7-h3 e conjugados anticorpo fármaco
CO2022001210A2 (es) Conjugados de il-2 y métodos de uso para tratar enfermedades autoinmunes
ECSP19000282A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco
BR112018075630A2 (pt) anticorpos anti-cd98 e conjugados de fármaco de anticorpo
BR112018075644A2 (pt) anticorpos anti-cd98 e conjugados de anticorpo e fármaco
MX2021015153A (es) Composicion farmaceutica parenteral de agonista dual de glp1/2.
BR112023001471A2 (pt) Composição farmacêutica de anticorpo anti-pd-1 e uso da mesma
ECSP21074141A (es) Composición farmacéutica acuosa de anticuerpo anti-il17a y su uso
BR112019005637A2 (pt) análogos da insulina com afinidade reduzida para o receptor de insulina e seu uso
BR112022013255A2 (pt) Conjugados anticorpo-fármaco específicos de sítio com ligantes contendo peptídeo
MX2022006082A (es) Composicion aglutinante que incluye un componente de base biologica.
AR106981A1 (es) Una composición antimicrobiana
MX2025005954A (es) Composicion del conjugado anticuerpo anti-her3-farmaco y uso farmaceutico de la misma
ECSP22047524A (es) Tieniloxazolonas y an?logos
CO2024000763A2 (es) Composiciones y métodos de los anticuerpos anti-pacap
BR112022020531A2 (pt) Composição farmacêutica
BR112022000760A2 (pt) Composições, método para preparar um conjugado de longa duração de um polipeptídeo fisiologicamente ativo e conjugado de fármaco de longa duração
CL2024002184A1 (es) Olanzapina, composiciones de la misma y métodos de uso de la misma
BR112023022445A2 (pt) Composição farmacêutica e uso da combinação farmacêutica
BR112023000585A2 (pt) Composição farmacêutica e uso da mesma
BR112022009658A2 (pt) Composição para preparar alulose e método para preparar alulose com o uso da mesma